-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 11 News On August 9, the Heilongjiang Medical Insurance Bureau issued a "Notice on Price Reduction of Certain Drugs", stating that after an enterprise's voluntary application, a total of 7 drugs announced price reductions
.
Among them, the price of Pfizer's clofenac soft capsules (61mg×30 capsules) was adjusted from 64,100 yuan/box to 24,650 yuan/box, and the price of each box was reduced by nearly 40,000 yuan, a drop of 61.
5%
.
In addition to Pfizer, in the first half of this year, Eli Lilly, Sanofi, Xi'an Janssen and other multinational pharmaceutical companies have successively adjusted the prices of their star innovative drugs in various places
.
The industry believes that these products have been significantly reduced in price or are preparing for entry into the national medical insurance catalogue
.
It remains to be seen whether this first price reduction approach will be effective .
The price reduction of some original research drugs.
High-priced rare-disease drugs have significantly reduced their
value.
It is of concern that the National Medical Insurance Administration recently announced the list of drugs that passed the preliminary formal review in the 2021 National Medical Insurance Drug List.
After review, 271 drugs passed the preliminary formal review.
Pfizer said Products that have voluntarily reduced prices are listed
.
It is understood that clofenac is a rare disease drug, and it is also the world's first and only drug approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
.
Generally, the price reduction of products before the adjustment of the medical insurance catalogue will be interpreted as an intention to enter medical insurance.
Is the price reduction of clofenac soft capsules in preparation for entering medical insurance? However, like most rare-disease drugs, chlorfenaric acid soft capsules are expensive, and even if the price is reduced, the general audience may not be able to afford the cost
.
The National Medical Insurance Bureau clearly stated that some of the more expensive drugs passed the preliminary formal review, which only indicated that the drug met the application requirements after the preliminary review and was qualified to enter the next adjustment link
.
Whether such drugs can eventually enter the National Medical Insurance Drug List must be subject to rigorous review including economics.
Exclusive drugs must undergo price negotiations, and only those who have successfully negotiated can enter the list
.
Generally speaking, the average drop in medical insurance negotiations is more than 50%
.
In 2019, there were 70 newly negotiated drugs, with an average price reduction of 60.
7%; in 2020, the average price reduction of newly negotiated drugs was over 50%
.
Clofloxacin soft capsule is a star product under Pfizer's market that is growing rapidly
.
According to its latest semi-annual report, the sales of Vyndamax in the second quarter reached US$501 million, an increase of 77%
.
On the basis of the 60% price reduction, whether chlorfenaric acid soft capsules can accept further price reductions under medical insurance negotiations, and how to maintain the global price system, deserves continued attention
.
CDK4 / 6 pass through Medicare Pfizer, Eli Lilly and compete for
the current round of negotiations in the health insurance directory, in addition to lonazolac limp capsules, another Pfizer product piperazine star Bo Xili also of concern, especially in its competing products Lilly Abbe With Sealy also entering the initial review list of the medical insurance catalogue, since piperazilil has failed to enter the medical insurance catalogue for two consecutive years, whether Pfizer will make a full effort this year remains to be seen in the industry
.
At the end of December 2020, Eli Lilly’s Abbexilide tablets were approved for listing in China, becoming the second CDK4/6 inhibitor to be listed in China after piperazil
.
At present, 4 CDK4/6 inhibitors have been marketed globally, and Pfizer’s piperacillil was the first to be approved, with a clear first-mover advantage
.
As Pfizer's most important oncology drug product, Pebacillil has global sales of 5.
392 billion U.
S.
dollars in 2020, a year-on-year increase of 9%
.
However, due to the competitive pressure of Eli Lilly’s Abbecill and Novartis’s Reboxili, and the failure of early HR+ and HER2- breast cancer adjuvant treatment trials, the sales of piperacillil continued to slow down, and sales in the first quarter of 2021 A decline of 7%, and the US market also experienced a decline in the second quarter
.
As a result of its victory in the clinical development competition for adjuvant treatments for early HR+/HER2- breast cancer, Abexili achieved sales revenue of US$610 million in the first half of 2021, a year-on-year increase of 54%.
.
Given that the patent of pibacillil will expire in 2023, many domestic pharmaceutical companies have already begun to deploy, and Qilu Pharmaceutical is the fastest
.
In December 2020, Qilu Pharmaceutical's 4 types of generic drugs were approved for listing, becoming the first domestic imitation of this variety
.
The original domestic CDK4/6 inhibitors are also actively deploying, and Hengrui is making the fastest progress
.
In April of this year, Hengrui's CDK4/6 inhibitor SHR6390 listing application is planned to be included in the priority review
.
For piperazil, because of Eli Lilly's participation, this year's medical insurance negotiations may usher in a backlash
.
In January this year, Pfizer also officially adjusted the price of piperacillil.
The price of the 125 mg specification dropped from 29799 yuan/bottle to 13,667 yuan/bottle, a decrease of 54%
.
More and more companies choose to cut prices
in advance.
In addition to Pfizer, in the first half of this year, multinational pharmaceutical companies such as Eli Lilly, Sanofi, and Xi'an Janssen also chose to actively cut prices for their star innovative drugs
.
On July 27, the Hunan Provincial Public Resources Trading Center issued a notice: Xi'an Janssen’s daletuzumab (400mg/20ml), the price dropped from 19710 yuan to 8512.
4 yuan, a decrease of 56.
8%
.
In addition, in March of this year, Xi’an Janssen’s Useltuzumab injection and Eli Lilly’s ichizumab injection voluntarily reduced prices on local procurement platforms, and Useltuzumab injection (130mg/26ml/bottle) went online.
The purchase price was adjusted from 18,500 yuan/bottle to 10,000 yuan/bottle, a decrease of about 45.
94%; the online purchase price of ichizumab injection (80mg/ml/bottle) was adjusted from 6,296 yuan/bottle to 2,896 yuan/bottle, The decrease was 54%
.
Sanofi’s Alixizumab voluntarily applied for a price reduction in Liaoning Province, adjusting the online price from 1888 yuan to 998 yuan, a reduction of about 47%
.
According to industry analysis, the high probability of successive price reductions of these products is to prepare for medical insurance negotiations.
.
For some products that "re-fight", such as competing products and similar products entering medical insurance, products that fail to enter medical insurance will face a passive situation
.
The failure of some original research drugs to break through medical insurance may be mainly due to the global pricing system, and the price may be difficult to meet the expected decline
.
The industry also predicts that some star drugs may make breakthroughs this year
.
From the perspective of the industry, medical insurance access price negotiation is an effective way to improve the availability of medicines
.
Some experts said that how to solve the accessibility of innovative drugs still requires joint efforts from multiple parties
.
Including innovative payment methods and the establishment of a diversified co-payment mechanism for sharing the cost of innovative drugs
.
Indeed, innovative drugs are in urgent need of innovative payment solutions.
With the rapid development of commercial insurance policies, especially the implementation of customized urban supplementary insurance (Puhuibao) in various places, the coverage of high-priced drugs inside and outside medical insurance can be achieved
.
Today, many multinational pharmaceutical companies and innovative pharmaceutical companies are also actively cooperating with commercial insurance
.
As for drugs for rare diseases, the National Medical Insurance Bureau has also made it clear that it adheres to the direction of basic insurance and includes drugs for rare diseases that meet the requirements into the scope of medical insurance payment
.
For special rare diseases with particularly high costs, we will work with relevant departments to explore mechanisms for guaranteeing drugs for rare diseases, and strive to reduce the burden on patients
.
.
Among them, the price of Pfizer's clofenac soft capsules (61mg×30 capsules) was adjusted from 64,100 yuan/box to 24,650 yuan/box, and the price of each box was reduced by nearly 40,000 yuan, a drop of 61.
5%
.
In addition to Pfizer, in the first half of this year, Eli Lilly, Sanofi, Xi'an Janssen and other multinational pharmaceutical companies have successively adjusted the prices of their star innovative drugs in various places
.
The industry believes that these products have been significantly reduced in price or are preparing for entry into the national medical insurance catalogue
.
It remains to be seen whether this first price reduction approach will be effective .
The price reduction of some original research drugs.
High-priced rare-disease drugs have significantly reduced their
value.
It is of concern that the National Medical Insurance Administration recently announced the list of drugs that passed the preliminary formal review in the 2021 National Medical Insurance Drug List.
After review, 271 drugs passed the preliminary formal review.
Pfizer said Products that have voluntarily reduced prices are listed
.
It is understood that clofenac is a rare disease drug, and it is also the world's first and only drug approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
.
Generally, the price reduction of products before the adjustment of the medical insurance catalogue will be interpreted as an intention to enter medical insurance.
Is the price reduction of clofenac soft capsules in preparation for entering medical insurance? However, like most rare-disease drugs, chlorfenaric acid soft capsules are expensive, and even if the price is reduced, the general audience may not be able to afford the cost
.
The National Medical Insurance Bureau clearly stated that some of the more expensive drugs passed the preliminary formal review, which only indicated that the drug met the application requirements after the preliminary review and was qualified to enter the next adjustment link
.
Whether such drugs can eventually enter the National Medical Insurance Drug List must be subject to rigorous review including economics.
Exclusive drugs must undergo price negotiations, and only those who have successfully negotiated can enter the list
.
Generally speaking, the average drop in medical insurance negotiations is more than 50%
.
In 2019, there were 70 newly negotiated drugs, with an average price reduction of 60.
7%; in 2020, the average price reduction of newly negotiated drugs was over 50%
.
Clofloxacin soft capsule is a star product under Pfizer's market that is growing rapidly
.
According to its latest semi-annual report, the sales of Vyndamax in the second quarter reached US$501 million, an increase of 77%
.
On the basis of the 60% price reduction, whether chlorfenaric acid soft capsules can accept further price reductions under medical insurance negotiations, and how to maintain the global price system, deserves continued attention
.
CDK4 / 6 pass through Medicare Pfizer, Eli Lilly and compete for
the current round of negotiations in the health insurance directory, in addition to lonazolac limp capsules, another Pfizer product piperazine star Bo Xili also of concern, especially in its competing products Lilly Abbe With Sealy also entering the initial review list of the medical insurance catalogue, since piperazilil has failed to enter the medical insurance catalogue for two consecutive years, whether Pfizer will make a full effort this year remains to be seen in the industry
.
At the end of December 2020, Eli Lilly’s Abbexilide tablets were approved for listing in China, becoming the second CDK4/6 inhibitor to be listed in China after piperazil
.
At present, 4 CDK4/6 inhibitors have been marketed globally, and Pfizer’s piperacillil was the first to be approved, with a clear first-mover advantage
.
As Pfizer's most important oncology drug product, Pebacillil has global sales of 5.
392 billion U.
S.
dollars in 2020, a year-on-year increase of 9%
.
However, due to the competitive pressure of Eli Lilly’s Abbecill and Novartis’s Reboxili, and the failure of early HR+ and HER2- breast cancer adjuvant treatment trials, the sales of piperacillil continued to slow down, and sales in the first quarter of 2021 A decline of 7%, and the US market also experienced a decline in the second quarter
.
As a result of its victory in the clinical development competition for adjuvant treatments for early HR+/HER2- breast cancer, Abexili achieved sales revenue of US$610 million in the first half of 2021, a year-on-year increase of 54%.
.
Given that the patent of pibacillil will expire in 2023, many domestic pharmaceutical companies have already begun to deploy, and Qilu Pharmaceutical is the fastest
.
In December 2020, Qilu Pharmaceutical's 4 types of generic drugs were approved for listing, becoming the first domestic imitation of this variety
.
The original domestic CDK4/6 inhibitors are also actively deploying, and Hengrui is making the fastest progress
.
In April of this year, Hengrui's CDK4/6 inhibitor SHR6390 listing application is planned to be included in the priority review
.
For piperazil, because of Eli Lilly's participation, this year's medical insurance negotiations may usher in a backlash
.
In January this year, Pfizer also officially adjusted the price of piperacillil.
The price of the 125 mg specification dropped from 29799 yuan/bottle to 13,667 yuan/bottle, a decrease of 54%
.
More and more companies choose to cut prices
in advance.
In addition to Pfizer, in the first half of this year, multinational pharmaceutical companies such as Eli Lilly, Sanofi, and Xi'an Janssen also chose to actively cut prices for their star innovative drugs
.
On July 27, the Hunan Provincial Public Resources Trading Center issued a notice: Xi'an Janssen’s daletuzumab (400mg/20ml), the price dropped from 19710 yuan to 8512.
4 yuan, a decrease of 56.
8%
.
In addition, in March of this year, Xi’an Janssen’s Useltuzumab injection and Eli Lilly’s ichizumab injection voluntarily reduced prices on local procurement platforms, and Useltuzumab injection (130mg/26ml/bottle) went online.
The purchase price was adjusted from 18,500 yuan/bottle to 10,000 yuan/bottle, a decrease of about 45.
94%; the online purchase price of ichizumab injection (80mg/ml/bottle) was adjusted from 6,296 yuan/bottle to 2,896 yuan/bottle, The decrease was 54%
.
Sanofi’s Alixizumab voluntarily applied for a price reduction in Liaoning Province, adjusting the online price from 1888 yuan to 998 yuan, a reduction of about 47%
.
According to industry analysis, the high probability of successive price reductions of these products is to prepare for medical insurance negotiations.
.
For some products that "re-fight", such as competing products and similar products entering medical insurance, products that fail to enter medical insurance will face a passive situation
.
The failure of some original research drugs to break through medical insurance may be mainly due to the global pricing system, and the price may be difficult to meet the expected decline
.
The industry also predicts that some star drugs may make breakthroughs this year
.
From the perspective of the industry, medical insurance access price negotiation is an effective way to improve the availability of medicines
.
Some experts said that how to solve the accessibility of innovative drugs still requires joint efforts from multiple parties
.
Including innovative payment methods and the establishment of a diversified co-payment mechanism for sharing the cost of innovative drugs
.
Indeed, innovative drugs are in urgent need of innovative payment solutions.
With the rapid development of commercial insurance policies, especially the implementation of customized urban supplementary insurance (Puhuibao) in various places, the coverage of high-priced drugs inside and outside medical insurance can be achieved
.
Today, many multinational pharmaceutical companies and innovative pharmaceutical companies are also actively cooperating with commercial insurance
.
As for drugs for rare diseases, the National Medical Insurance Bureau has also made it clear that it adheres to the direction of basic insurance and includes drugs for rare diseases that meet the requirements into the scope of medical insurance payment
.
For special rare diseases with particularly high costs, we will work with relevant departments to explore mechanisms for guaranteeing drugs for rare diseases, and strive to reduce the burden on patients
.
